A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avi
Latest Information Update: 24 Feb 2025
At a glance
- Drugs Amikacin (Primary) ; Azithromycin; Ethambutol
- Indications Lung disorders; Mycobacterium avium complex infections; Nontuberculous mycobacterium infections
- Focus Registrational; Therapeutic Use
- Acronyms ARISE
- Sponsors Insmed
- 22 May 2024 Results assessing the impact of amikacin liposome inhalation suspension (ALIS) on microbiologic outcomes, presented at the 120th International Conference of the American Thoracic Society
- 22 May 2024 Results assessing the impact of amikacin liposome inhalation suspension (ALIS) treatment on respiratory symptoms, using the QOL-B RD data, presented at the 120th International Conference of the American Thoracic Society
- 22 May 2024 Results assessing Patient-reported Outcome Instruments and Assess Microbiological Outcomes presented at the 120th International Conference of the American Thoracic Society